KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Castle Biosciences (CSTL) Receivables - Net (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Receivables - Net for 8 consecutive years, with $43.4 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net fell 15.3% to $43.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.4 million through Dec 2025, down 15.3% year-over-year, with the annual reading at $43.4 million for FY2025, 15.3% down from the prior year.
  • Receivables - Net hit $43.4 million in Q4 2025 for Castle Biosciences, down from $49.5 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $56.4 million in Q1 2025 to a low of $14.3 million in Q1 2021.
  • Historically, Receivables - Net has averaged $34.1 million across 5 years, with a median of $34.2 million in 2023.
  • Biggest five-year swings in Receivables - Net: soared 63.15% in 2023 and later fell 15.3% in 2025.
  • Year by year, Receivables - Net stood at $17.3 million in 2021, then skyrocketed by 35.84% to $23.5 million in 2022, then soared by 63.15% to $38.3 million in 2023, then soared by 33.72% to $51.2 million in 2024, then decreased by 15.3% to $43.4 million in 2025.
  • Business Quant data shows Receivables - Net for CSTL at $43.4 million in Q4 2025, $49.5 million in Q3 2025, and $52.3 million in Q2 2025.